ATHE vs. CMMB, AEZS, ADXN, GRTX, GHSI, MTEM, ERNA, GRAY, ABVC, and MIRA
Should you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Chemomab Therapeutics (CMMB), Aeterna Zentaris (AEZS), Addex Therapeutics (ADXN), Galera Therapeutics (GRTX), Guardion Health Sciences (GHSI), Molecular Templates (MTEM), Eterna Therapeutics (ERNA), Graybug Vision (GRAY), ABVC BioPharma (ABVC), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical preparations" industry.
Alterity Therapeutics (NASDAQ:ATHE) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, community ranking, valuation, earnings, risk and dividends.
Alterity Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.
Alterity Therapeutics currently has a consensus price target of $7.00, indicating a potential upside of 230.19%. Chemomab Therapeutics has a consensus price target of $5.67, indicating a potential upside of 560.45%. Given Chemomab Therapeutics' higher probable upside, analysts plainly believe Chemomab Therapeutics is more favorable than Alterity Therapeutics.
Alterity Therapeutics has higher revenue and earnings than Chemomab Therapeutics.
2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Chemomab Therapeutics received 13 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. Likewise, 61.54% of users gave Chemomab Therapeutics an outperform vote while only 60.00% of users gave Alterity Therapeutics an outperform vote.
Alterity Therapeutics' return on equity of 0.00% beat Chemomab Therapeutics' return on equity.
In the previous week, Chemomab Therapeutics had 9 more articles in the media than Alterity Therapeutics. MarketBeat recorded 11 mentions for Chemomab Therapeutics and 2 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 1.25 beat Chemomab Therapeutics' score of 0.36 indicating that Alterity Therapeutics is being referred to more favorably in the media.
Summary
Alterity Therapeutics beats Chemomab Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Alterity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alterity Therapeutics Competitors List
Related Companies and Tools
